Imagine a world where medical treatments are perfectly tailored to your unique genetic makeup. Sounds like science fiction, right? But thanks to groundbreaking advances in genomics, this future is closer than you think. The key? The human pangenome.
In May 2023, the Human Pangenome Reference Consortium (HPRC) unveiled the first draft of the human pangenome reference sequence. This wasn't just another genome map; it was a revolutionary leap forward! This groundbreaking project incorporated genomic data from 47 diverse individuals, representing a much broader spectrum of human genetic variation than ever before. The result? A staggering 119 million extra base pairs of euchromatic polymorphic sequences added to our understanding of the human genetic code. Just a month later, in June 2023, the Chinese Pangenome Consortium (CPC) added fuel to the fire by publishing 116 high-quality sequences, meticulously mapped at the haplotype level, derived from 36 distinct ethnic minority groups within China. This contribution injected another 189 million base pairs of previously unknown sequences into the pangenome, further enriching our understanding of human genetic diversity.
These monumental achievements have exposed the inherent limitations of relying on a single, traditional reference genome. The old model simply couldn't capture the full richness and complexity of human genetic variation. The pangenome, by contrast, provides a more comprehensive framework for understanding disease susceptibility and the genetic underpinnings of ethnic differences. Think of it like this: the old reference genome was like a single, outdated map of the world. The pangenome is a dynamic, constantly updated atlas that reflects the true diversity of the human population.
Yingyan Yu, from Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and Hongzhuan Chen, from Shanghai University of Traditional Chinese Medicine, have provided a comprehensive overview of the human pangenome's development and its profound implications for precision medicine in their recent commentary. Their work highlights the transformative potential of this technology.
The journey to the pangenome began with a pivotal discovery: the DNA double helix. 2023 marked the 70th anniversary of this watershed moment. Back in April 1953, Watson and Crick published their groundbreaking paper in Nature, proposing the double-helix structure of DNA and elucidating its replication mechanism. This discovery, built upon the crucial "Photo 51" X-ray crystallographic image of DNA captured by Rosalind Franklin’s team at King’s College London in 1952, laid the very foundation for genetic decoding. It’s a story of collaboration and scientific breakthroughs that continues to inspire.
The invention of first-generation sequencing technology by Sanger in 1977 paved the way for the ambitious Human Genome Project (HGP) in the 1990s. Chinese scientists played a vital role, contributing 1% of the sequencing work. The HGP, completed in 2003, successfully sequenced over 90% of the human genome. But here's the catch: due to technological constraints at the time, the initial reference genome was incomplete, riddled with sequence gaps, and failed to fully represent population-specific variations. The advent of next-generation sequencing technology in 2005, with its dramatically reduced sequencing costs, ignited a new era of in-depth exploration of genetic diversity, ultimately giving rise to pangenome research.
The term "pangenome" itself comes from ancient Greek, meaning "whole." Simply put, it represents the totality of genetic material found across all individuals within a species. It's comprised of three key components: core genes (shared by everyone), distributed genes (present in some individuals but absent in others), and population-specific genes (unique to a particular ethnic group). This concept first emerged in 2005 in a study on Streptococcus agalactiae and was subsequently extended to plant and human research. In 2010, Chinese scientists took a crucial step by integrating the genomes of an Asian and an African individual, uncovering approximately 5 Mb of novel sequences that were missing from the existing reference genome. This work laid a critical foundation for the construction of the human pangenome.
But here's where it gets controversial... Compared to microbial genomes, the human genome generates a truly massive amount of data. Therefore, pangenome research relies on advanced methodologies, including high-performance computing clusters and sophisticated automated analysis tools. Some argue that the sheer scale and complexity of human genomic data present insurmountable challenges. Do you agree?
A core challenge in pangenome research is the ability to efficiently process these enormous datasets. A collaborative team from Shanghai Jiao Tong University and Shanghai University of Traditional Chinese Medicine developed the HUman Pan-genome ANalysis (HUPAN) automated pipeline. HUPAN leverages high-performance computing to enable large-scale whole-genome sequencing (WGS) data analysis. This powerful tool was even recognized as one of the "Top 10 Algorithms and Tools for Bioinformatics in China" in 2019. Technically speaking, third-generation sequencing, with its ability to generate longer read lengths, overcomes the limitations of gene annotation inaccuracies associated with second-generation sequencing. This is a huge leap forward for accuracy and completeness.
In the realm of cancer research, the team utilized HUPAN to analyze 185 pairs of gastric cancer tissue samples from Han Chinese individuals, leading to the construction of the first human gastric cancer pangenome. And this is the part most people miss... This pangenome included a staggering 80.88 Mb of previously unmapped novel sequences. The analysis revealed that the deletion frequency of distributed genes (such as GSTM1 and SIGLEC14) is significantly higher in the Han population compared to Western populations. This provides a crucial genetic explanation for the ethnic susceptibility to gastric cancer. Furthermore, the researchers predicted 14 novel genes from these previously unknown sequences. One standout gene, GC0643, mapped to the 9q34.2 locus. In vitro experiments confirmed that GC0643 inhibits cancer cell growth and promotes apoptosis. It has since been registered in the NCBI database (GenBank: MW194843.1).
The maturation of pangenome technology is ushering in the era of individualized genomics. Data from the HPRC indicates that genomic differences between humans account for approximately 0.4% of the entire genome. These structural variations within this seemingly small fraction may be strongly linked to disease susceptibility. For example, the deletion of SIGLEC14 in the Han population may compromise innate immunity, while the deletion of ACOT1 might influence cancer development through fatty acid metabolism. Notably, some of these variations overlap with the Neanderthal genome, offering exciting clues for human evolution research. Could this be a key to understanding our past?
Looking ahead, "tailored" treatments based on the pangenome promise to revolutionize disease diagnosis and drug selection. Imagine optimizing treatment strategies based on your unique genetic profile. The pangenome can also shed light on ethnic differences in disease incidence and clarify the reasons behind varying drug responses. This will ultimately propel precision medicine into a new era, where treatments are not just effective, but personalized. But the question remains: will everyone have equal access to these advanced technologies? What are your thoughts on the ethical implications of pangenome-based medicine? Share your opinions in the comments below!
You can explore the detailed information through this link: https://journal.hep.com.cn/fmd/EN/10.1007/s11684-023-1039-1.
